<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933372</url>
  </required_header>
  <id_info>
    <org_study_id>HUM00093188</org_study_id>
    <nct_id>NCT02933372</nct_id>
  </id_info>
  <brief_title>Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 &amp; 2 - Proj #3</brief_title>
  <acronym>UdallP3</acronym>
  <official_title>Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 &amp; 2 - Projects #3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Varying oral doses of Varenicline (VCN), starting with very low doses, will be administered&#xD;
      to participants with Parkinson's Disease (PD) or healthy controls without PD for several&#xD;
      days. Positron emission tomography (PET) scans after administration of VCN will be used to&#xD;
      determine the lowest oral dose of VCN producing an adequate brain level of VCN. These&#xD;
      experiments (1 &amp; 2) will be used to determine an appropriate oral dose of VCN to administer&#xD;
      to PD participants for experiment 3 of the study (see NCT04403399).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To demonstrate that α4β2* nAChRs are appropriate therapeutic targets in Parkinson's Disease&#xD;
      (PD), it is necessary to study key pharmacokinetic-pharmacodynamic features of α4β2* nAChR in&#xD;
      the context of the PD brain with loss of nerve cells that produce the neurotransmitter&#xD;
      acetylcholine, a pathologic environment in which they may exhibit unique features. This&#xD;
      personalized medicine approach focuses our studies on the subgroup of PD subjects with loss&#xD;
      of nerve cells that produce the neurotransmitter acetylcholine identified by Project II and&#xD;
      the Clinical Resource Core. The investigators will assess α4β2* nAChR features using PET&#xD;
      imaging with the α4β2* nAChR ligand [18 - Fluorine] flubatine, subacute administration of the&#xD;
      α4β2* nAChR partial agonist Varenicline (VCN), and laboratory measures of gait, balance, and&#xD;
      attention. The investigators will use [18 - Fluorine] flubatine PET to assess VCN occupancy&#xD;
      of brain α4β2* nAChRs (experiments 1 &amp; 2). VCN will be administered to both PD participants&#xD;
      (experiment 1) and healthy controls (experiment 2) and both populations will undergo a&#xD;
      flubatine PET scan to assess VCN occupancy. Using this PET data to select an appropriate VCN&#xD;
      dose, the investigators will perform a pharmacodynamic study (experiment 3) with subacute VCN&#xD;
      administration to determine if α4β2* nAChR stimulation improves laboratory measures of gait&#xD;
      function, postural control, and attentional function in PD subjects with loss of nerve cells&#xD;
      that produce the neurotransmitter acetylcholine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 5, 2015</start_date>
  <completion_date type="Actual">June 26, 2019</completion_date>
  <primary_completion_date type="Actual">June 26, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All participants (Parkinson's disease patients and healthy controls) will receive the study drug varenicline.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Varenicline Occupancy of alpha4beta2* Nicotinic Acetylcholine Receptors</measure>
    <time_frame>15 days</time_frame>
    <description>Varenicline occupancy of alpha4beta2* nicotinic acetylcholine receptors (nAChR) was assessed with ascending doses of varenicline and the selective alpha4beta2* nAChR positron emission tomography (PET) ligand [18F]Flubatine. Alpha4beta2* nAChR agonists may induce nAChR expression. Consequently, we imaged participants at the end of their drug exposure periods (Day 10) and again after 5 days (~5 half-lives) of washout from drug exposure (Day 15). We used the difference between the two PET scans, (Day 10 - Day 15)/Day 15 x 100%, to determine the receptor occupancy of alpha4beta2* nicotinic acetylcholine receptors (nAChR) by each dose of varenicline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>Parkinson's Disease Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments of severity of Parkinson disease (PD) and cognition are performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. The PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments for presence of Parkinson disease (PD) and cognition are performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized for both Parkinson's disease participants and healthy volunteers were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day. A fourth dosing group of 1 mg varenicline twice a day was studied in Parkinson's disease participants, but not in healthy volunteers.</description>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Parkinson's Disease Patients</arm_group_label>
    <other_name>Chantix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. PD diagnosis will be based on the United Kingdom Parkinson's Disease Society Brain&#xD;
             Bank Research Center (UKPDSBRC) clinical diagnostic criteria. The investigators will&#xD;
             enrich the cohort by recruiting subjects at modified Hoehn and Yahr stages 2 or&#xD;
             higher, duration of motor disease 5 years or longer, age &gt;65 years, or the Postural&#xD;
             Instability and Gait Disorder (PIGD) phenotype. Duration of motor disease will be&#xD;
             defined as the time between onset of motor symptoms and time of entry into the study.&#xD;
             The PIGD phenotype is defined as described previously. PD subjects with defined&#xD;
             cholinergic deficits will be recruited as described in Project II. PD subjects will&#xD;
             have cortical cholinergic deficits based on 5th percentile cutoff of the normal&#xD;
             controls as defined previously.&#xD;
&#xD;
          2. Stable dopaminergic replacement therapy for 3 months prior to enrollment and expected&#xD;
             to maintain stable dopaminergic therapy for duration of study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other disorders which may resemble PD with or without dementia, such as vascular&#xD;
             dementia, normal pressure hydrocephalus, progressive supranuclear palsy, multiple&#xD;
             system atrophy, corticobasal ganglionic degeneration, or toxic causes of parkinsonism.&#xD;
             Prototypical cases have distinctive clinical profiles, like vertical supranuclear gaze&#xD;
             palsy, early and severe dysautonomia or appendicular apraxia, which may differentiate&#xD;
             them from idiopathic PD. The use of the UKPDSBRC clinical diagnostic criteria for PD&#xD;
             will mitigate the inclusion of subjects with atypical parkinsonism and all&#xD;
             participants will undergo [11-Carbon]dihydrotetrabenazine PET to confirm striatal&#xD;
             dopaminergic denervation.&#xD;
&#xD;
          2. Subjects on neuroleptic, anticholinergic (trihexphenidyl, benztropine), or&#xD;
             cholinesterase inhibitor drugs.&#xD;
&#xD;
          3. Current or previous (within last 6 months) use of any product or medication containing&#xD;
             nicotinic agents,including use of tobacco products such as cigarettes, cigars, pipes,&#xD;
             chewing tobacco, etc., electronic cigarettes, over-the-counter nicotine patches,&#xD;
             chewing gum containing nicotine, or varenicline.&#xD;
&#xD;
          4. Evidence of a stroke or mass lesion on structural brain imaging (MRI).&#xD;
&#xD;
          5. Participants in whom magnetic resonance imaging (MRI) is contraindicated including,&#xD;
             but not limited to, those with a pacemaker, presence of metallic fragments near the&#xD;
             eyes or spinal cord, or cochlear implant.&#xD;
&#xD;
          6. Severe claustrophobia precluding MR or PET imaging&#xD;
&#xD;
          7. Subjects limited by participation in research procedures involving ionizing radiation.&#xD;
&#xD;
          8. Pregnancy (test within 48 hours of each PET session) or breastfeeding.&#xD;
&#xD;
          9. Significant risk of cardiovascular event.&#xD;
&#xD;
         10. Active, significant mood disorder.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger L Albin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 6, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <results_first_submitted>January 4, 2021</results_first_submitted>
  <results_first_submitted_qc>January 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 12, 2021</results_first_posted>
  <disposition_first_submitted>May 13, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>May 13, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 18, 2020</disposition_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Roger L. Albin</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02933372/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02933372/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Parkinson's Disease Patients</title>
          <description>Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized were 0.25mg once a day, 0.25mg twice a day, 0.5mg twice a day and 1mg twice a day.</description>
        </group>
        <group group_id="P2">
          <title>Healthy Controls</title>
          <description>Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All consented participants</population>
      <group_list>
        <group group_id="B1">
          <title>Parkinson's Disease Patients</title>
          <description>Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized were 0.25mg once a day, 0.25mg twice a day, 0.5mg twice a day and 1mg twice a day.</description>
        </group>
        <group group_id="B2">
          <title>Healthy Controls</title>
          <description>: Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.3" spread="5.20"/>
                    <measurement group_id="B2" value="66.4" spread="8.95"/>
                    <measurement group_id="B3" value="66.9" spread="6.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>MDS-UPDRS III</title>
          <description>Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (motor examination) includes 18 items (33 scores). Each item scores from 0 (normal) to 4 (severe) and total score is obtained from the sum of the corresponding item scores. The minimum is 0, maximum is 132, with higher scores indicating more disability.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.9" spread="12.83"/>
                    <measurement group_id="B2" value="3.5" spread="1.84"/>
                    <measurement group_id="B3" value="20.5" spread="17.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Geriatric Depression Scale</title>
          <description>Geriatric Depression Scale (GDS) is a 30-item questionnaire (long form) to measure depression in the older population. Participants are asked to respond yes or no to how they felt over the past week. Scores range from 0 to 30, with higher scores indicating more severe depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.2" spread="3.75"/>
                    <measurement group_id="B2" value="1.6" spread="2.01"/>
                    <measurement group_id="B3" value="2.6" spread="3.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montreal Cognitive Assessment</title>
          <description>Montreal Cognitive Assessment (MoCA) is a questionnaire assessing cognitive dysfunction. It assesses attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The score ranges from 0 to 30, with lower scores indicating more severe cognitive impairment.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.5" spread="1.73"/>
                    <measurement group_id="B2" value="26.8" spread="2.30"/>
                    <measurement group_id="B3" value="26.0" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Varenicline Occupancy of alpha4beta2* Nicotinic Acetylcholine Receptors</title>
        <description>Varenicline occupancy of alpha4beta2* nicotinic acetylcholine receptors (nAChR) was assessed with ascending doses of varenicline and the selective alpha4beta2* nAChR positron emission tomography (PET) ligand [18F]Flubatine. Alpha4beta2* nAChR agonists may induce nAChR expression. Consequently, we imaged participants at the end of their drug exposure periods (Day 10) and again after 5 days (~5 half-lives) of washout from drug exposure (Day 15). We used the difference between the two PET scans, (Day 10 - Day 15)/Day 15 x 100%, to determine the receptor occupancy of alpha4beta2* nicotinic acetylcholine receptors (nAChR) by each dose of varenicline.</description>
        <time_frame>15 days</time_frame>
        <population>All consented and treated participants who had adequate PET scans. In Parkinson's Disease cohort, there were technical difficulties with PET scans in 5 participants. In the Healthy Controls cohort, one participant's data was excluded because of suspected covert tobacco abuse and there were technical difficulties with the PET scan for one participant.</population>
        <group_list>
          <group group_id="O1">
            <title>Parkinson's Disease Patients</title>
            <description>Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments of severity of Parkinson disease (PD) and cognition are performed.&#xD;
Varenicline: Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized were 0.25mg once a day, 0.25mg twice a day, 0.5mg twice a day and 1mg twice a day.&#xD;
[18-Fluorine] Flubatine PET Scan: Participants will undergo 2 different PET scanning sessions. Radiotracers will be injected into the participant's vein through an IV (intravenous catheter or plastic &quot;tube&quot; inserted in an arm vein). A tracer refers to a small amount of a radioactive substance that does not alter body function.&#xD;
Evaluation by Investigator: Participants will undergo cognitive testing, a physical exam, and gait and posture assessments</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>Participants take varenicline for several days and have two Positron Emission Tomography (PET) scans. The PET scans are used to estimate how much varenicline is actually in the brain. Safety monitoring with clinical assessments for presence of Parkinson disease (PD) and cognition are performed.&#xD;
Varenicline: Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized were 0.25mg once a day, 0.25mg twice a day, 0.5mg twice a day and 1mg twice a day.&#xD;
[18-Fluorine] Flubatine PET Scan: Participants will undergo 2 different PET scanning sessions. Radiotracers will be injected into the participant's vein through an IV (intravenous catheter or plastic &quot;tube&quot; inserted in an arm vein). A tracer refers to a small amount of a radioactive substance that does not alter body function.&#xD;
Evaluation by Investigator: Participants will undergo cognitive testing, a physical exam, and gait and posture assessments</description>
          </group>
        </group_list>
        <measure>
          <title>Varenicline Occupancy of alpha4beta2* Nicotinic Acetylcholine Receptors</title>
          <description>Varenicline occupancy of alpha4beta2* nicotinic acetylcholine receptors (nAChR) was assessed with ascending doses of varenicline and the selective alpha4beta2* nAChR positron emission tomography (PET) ligand [18F]Flubatine. Alpha4beta2* nAChR agonists may induce nAChR expression. Consequently, we imaged participants at the end of their drug exposure periods (Day 10) and again after 5 days (~5 half-lives) of washout from drug exposure (Day 15). We used the difference between the two PET scans, (Day 10 - Day 15)/Day 15 x 100%, to determine the receptor occupancy of alpha4beta2* nicotinic acetylcholine receptors (nAChR) by each dose of varenicline.</description>
          <population>All consented and treated participants who had adequate PET scans. In Parkinson's Disease cohort, there were technical difficulties with PET scans in 5 participants. In the Healthy Controls cohort, one participant's data was excluded because of suspected covert tobacco abuse and there were technical difficulties with the PET scan for one participant.</population>
          <units>percentage of VCN-alpha4beta2* nAChRs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0.25 mg once daily Varenicline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.0" spread="4.9"/>
                    <measurement group_id="O2" value="67.9" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.25 mg twice daily Varenicline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.7" spread="8.0"/>
                    <measurement group_id="O2" value="70.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0.5 mg twice daily Varenicline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3" spread="5.0"/>
                    <measurement group_id="O2" value="69.6" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 mg twice daily Varenicline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.5" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>15 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Parkinson's Disease Patients</title>
          <description>Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized were 0.25mg once a day, 0.25mg twice a day, 0.5mg twice a day and 1mg twice a day.</description>
        </group>
        <group group_id="E2">
          <title>Healthy Controls</title>
          <description>Participants take varenicline for 10 days. Each participant will be on one dosage throughout the 10 days, but not all participants receive the same dosage. The dosages that were utilized were 0.25mg once a day, 0.25mg twice a day, and 0.5mg twice a day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tiredness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach cramping</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ended PET scan prior to completion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Blood in urine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Cathie Spino, Research Professor of Biostatistics</name_or_title>
      <organization>U of Michigan</organization>
      <phone>7346155469</phone>
      <email>spino@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

